Strike the right 'value balance'
Providing real value for all stakeholders means whittling down costs and improving patient outcomes. In other words, doing more with less.
To achieve this, a collaborative effort is required. Satisfying regulatory bodies and payers, and delivering value-based evidence that paves the way for patient access, means better communication and understanding between all parties is a priority. And that includes competing pharma brands!
Meanwhile, as we strive to meet the demands of payers looking for cost-effective products, R&D budgets are skyrocketing. Drugs that deliver optimal patient outcomes, satisfy payers and still bring pharma a healthy ROI are becoming harder to create and develop.
Achieving patient access for a tried, tested and approved drug begins with robust clinical trials and rigorously analyzed real life evidence. But there must also be a strong business case for finding disease solutions. RWE is fast proving itself to be worth the extra expense incurred upfront, sharpening a brand's competitive edge throughout the lifecycle.
If any of this resonates with your vision for the future of your business - you have a duty to attend this meeting!